Halozyme Therapeutics, Inc. Website

Halozyme Therapeutics, Inc.

NasdaqGS-HALO

Company Overview

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

  • Name

    Halozyme Therapeutics, Inc.

  • CEO

    Helen I. Torley

  • Website

    halozyme.com

  • Sector

    Biotechnology

  • Year Founded

    1998

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

What's happening

Nov 12, 2025 - Dec 12, 2025

Halozyme Therapeutics Faces Significant Challenges Amid Leadership Changes and Analyst Downgrades

  • Halozyme Therapeutics Inc. experienced a notable decline in stock performance, with an overall movement of -10.7% over the past month.
  • The downgrade from Goldman Sachs significantly impacted investor sentiment, shifting its rating from Neutral to Sell with a price target of $56.00.
  • Despite some positive news regarding patent litigation, these developments were insufficient to counteract the prevailing bearish sentiment surrounding the company.

Over the past month, Halozyme Therapeutics Inc. saw a substantial decrease in its stock value, registering an overall decline of -10.7%. This downturn was largely driven by several negative events that influenced market reactions and investor confidence. A key factor was Goldman Sachs' downgrade of the company's stock rating from Neutral to Sell on December 4, which coincided with a sharp drop of 3.3%. Such analyst outlooks can have significant effects on stock prices.

The company also faced challenges related to executive transitions that further contributed to its declining performance. On November 25, Halozyme announced a CFO transition plan that led to an additional decline of 1.7%, raising concerns among investors about leadership stability during this critical period as it prepared for participation in important industry conferences focused on showcasing innovative drug delivery solutions.

Despite these setbacks, there were instances where positive news provided temporary support for HALO's stock price throughout the month. For example, on December 5, a preliminary injunction against Merck's Keytruda subcutaneous formulation due to patent infringement resulted in a bullish move of 1.2%. Additionally, HC Wainwright & Co.'s reiteration of its Buy rating on November 28 offered brief encouragement for investors.

However, these positive developments could not offset the overarching bearish sentiment stemming from downgrades and leadership changes; consequently HALO continued underperforming relative to broader market indices and sector benchmarks during this timeframe. The S&P 500 recorded modest gains at +0.7%, positioning Halozyme’s performance at an underperformance rate of -11.4% relative to this index while also lagging behind both this index and the Health Care sector (XLV), where it underperformed by -12.6%.

NasdaqGS:HALO